GenEdit is pioneering advancements in genetic medicine through its innovative delivery platform, NanoGalaxy®. This proprietary technology addresses the significant challenge of delivering genetic therapies effectively to target tissues, which has historically limited the potential benefits of such treatments. The NanoGalaxy platform utilizes a diverse library of non-viral, non-lipid polymer nanoparticles, enabling the identification of tissue-selective polymers through an iterative screening process. This systematic approach allows GenEdit to optimize the delivery of genetic medicines, ensuring that therapeutic payloads reach the specific organs and cell types where they can provide the most benefit.

The versatility of GenEdit's polymer nanoparticles is a key feature, as they can encapsulate a wide range of therapeutic payloads, including nucleic acids and proteins, while maintaining low immunogenicity. This characteristic not only allows for repeated dosing without the risk of immune response but also expands the potential patient population that can benefit from these therapies. Furthermore, the manufacturing process for these nanoparticles is designed for scalability and reproducibility, facilitating the development of cost-effective solutions for genetic medicine. Overall, GenEdit's focus on tissue selectivity, payload flexibility, and ease of manufacture positions it at the forefront of the genetic medicine landscape, aiming to address high unmet medical needs.

United States

GenEdit is revolutionizing genetic medicines by developing innovative therapies through targeted delivery of genetic medicines.

GenEdit

Company Details